<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622100</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2015-11</org_study_id>
    <nct_id>NCT02622100</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice</brief_title>
  <acronym>IRIS BVS</acronym>
  <official_title>Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duk-Woo Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative effectiveness and safety of
      Bioresorbable Vascular Scaffold compared to other (drug eluting stents) DES.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite event</measure>
    <time_frame>1 year</time_frame>
    <description>The number of events with the first occurrence of a composite event(death, non-fatal myocardial infarction, target vessel revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of death or myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event of cardiac death or myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.
Clinical-driven Clinically indicated angiography at follow-up shows a percent diameter stenosis ≥ 50% (core lab QCA assessment) and if one of the following occurs: (1) a positive history of recurrent angina pectoris, presumably related to the target vessel; (2) objective signs of ischemia at rest (ECG changes) of during exercise test (or equivalent), presumably related to the target vessel; (3) abnormal results of any invasive functional diagnostic test (eg, Doppler flow velocity reserve, fractional flow reserve).
Ischemia-driven if one of followings of above-mentioned symptom (clinical-driven) or sign of ischemia or diameter stenosis ≥ 70 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLRs should be classified prospectively as clinically indicated or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement. The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>5 years</time_frame>
    <description>DEFINITE stent thrombosis : acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE stent thrombosis : unexplained death within 30 days or target-vessel infarction without angiographic information Academic Research Consortium (ARC) stent thrombosis is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute stent thrombosis: 0-24 hours after stent implantation; Subacute stent thrombosis: &gt;24 hours to 30 days post; late stent thrombosis: &gt;30 days to 1 year post; Very late stent thrombosis: &gt;1 year post;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>3 days</time_frame>
    <description>Defined as mean lesion diameter stenosis ≤50% and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable Vascular Scaffold</intervention_name>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Bioresorbable Vascular Scaffold
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 and more

          -  Intervention with Bioresorbable Vascular Scaffold

          -  Agreed with written informed consent form

        Exclusion Criteria:

          -  Bypass graft surgery (CABG) recommended

          -  Lesion with previous bypass graft surgery (CABG)

          -  Severe calcification and/or severe tortuosity

          -  Contraindication to antiplatelet agent or Inability to take dual antiplatelet therapy
             within 1 year

          -  Life expectancy of 1year and under

          -  Subjects scheduled to receive cardiac surgery or serious non-cardiac surgery

          -  Cardiac shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young-Hee Kim, Project leader</last_name>
    <email>cvcrc2@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hee Kim, Project leader</last_name>
      <email>cvcrc2@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Duk-woo Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <email>heartsk@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Ki Lee, MD</last_name>
      <email>mdbklee@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Bong-Ki Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Dae-jeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Wan Choi, MD</last_name>
      <email>siwanc@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Si-wan Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kee-Sik Kim, MD</last_name>
      <email>kks7379@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kee-Sik Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-wook Nam, MD</last_name>
      <email>ncwcv@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Chang-wook Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-ho Her, MD</last_name>
      <email>hhhsungho@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sung-ho Her, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-yong Yoo, MD</last_name>
      <email>bovio@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sang-yong Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Keun Ahn, MD</last_name>
      <email>cecilyk@chonnam.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Keun Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChonBuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jei-keun Chae, MD</last_name>
      <email>jkchae@chonbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jei-keun Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <email>kmh60@damc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Un Na, MD</last_name>
      <email>swrha617@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-Un Na, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Hospital</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-jang Kim, MD</last_name>
      <email>mdwjkim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Won-jang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-seok Shin, MD</last_name>
      <email>sesim98@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Eun-seok Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Woo Park</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Bioresorbable Vascular Scaffold</keyword>
  <keyword>Routine Clinical Practice</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

